Growth in the infertility treatment market is primarily driven by factors such as the declining fertility rate, rising number of fertility clinics worldwide, technological advancements, and increasing public-private investments, funds, and grants. However, the high procedural costs of assisted reproductive technology procedures in developed markets and unsupportive government regulations for certain infertility treatment options are expected to limit market growth to a certain extent.
The coronavirus pandemic is currently presenting various challenges to clinical healthcare providers and patients across the globe. Logistical issues, managing patients with the disease, prioritizing patients with comorbidities and pre-existing conditions, and protecting public & hospital frontline workers from exposure to the COVID-19 infection are the major challenges faced by healthcare systems across the globe.
During the COVID-19 pandemic, a 90% drop was observed in the number of people undergoing IVF cycles. The spread of COVID-19 has not only impacted fertility clinics owing to the cancellation of IVF treatments but has also impacted fertility decisions among couples who were opting for IVF treatment before the pandemic.
Global fertility rates are projected to decline to 2.4 children per woman by 2030 and 2.2 children per woman by 2050. This declining fertility rate has led to a significant increase in the demand for infertility treatment products that determine the fertility window in males and females.
For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43497112
Emerging markets such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities for players in the infertility treatment market. The infertility treatment market in Asia and other emerging countries is characterized by the growing focus on healthcare infrastructural improvements.
Additionally, the medical tourism industry in emerging countries is thriving owing to a number of factors. In Asia, healthcare facilities are of high quality, treatment procedures are affordable, and many of the doctors and surgeons are trained and educated in the top institutes in the US and Europe. Emerging countries such as India, China, Singapore, Thailand, Brazil, and Malaysia present significant opportunities for the growth of the infertility treatment market.
The high growth in this owes to the technological advancements and presence of well-established players with strong product portfolio. Along with this growing focus of players towards base expansion through adopting various strategies such as new equipment launch, showcase across the globe is likely to contribute towards the growth of the segment.
Key Market Players
The prominent players operating in the global infertility treatment market include The Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher Scientific, Inc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Biomedx (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker Company, Inc. (US), Kitazato Corporation (Japan), Rocket Medical plc (UK), IHMedical A/S (Denmark), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), MedGyn Products, Inc. (US).
Recent Developments
- In 2021, CooperSurgical announced a partnership with Virtus Health to strengthen its fertility technology, increasing the accessibility of advanced treatment to infertile couples.
- In 2021, Hamilton Thorne Ltd. received FDA approval for the commercialization of the GYNEMED GM501, a ready-to-use medium designed for in vitro washing and handling procedures of human oocytes and embryos in the US and Europe.
- In 2020, Genea Biomedx (Australia) collaborated with Hamilton Thorne to commercialize Genea Biomedx’s (Australia) fertility products in the US and Canada.
